Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Oppenheimer Maintains Outperform on Prometheus Biosciences, Raises Price Target to $125

Oppenheimer analyst Jeff Jones maintains Prometheus Biosciences (NASDAQ:RXDX) with a Outperform and raises the price target from $61 to $125.
byBenzinga Newsdesk
December 8, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Oppenheimer analyst Jeff Jones maintains Prometheus Biosciences (NASDAQ:RXDX) with a Outperform and raises the price target from $61 to $125.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts